전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 갱신 권장 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs

데이터 갱신 주기입니다. 갱신 대기 7,609개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleUniversity College, LondonPhase 2

rAAV 2/2.hRPE65p.hRPE65 (tgAAG76, tgAAG76 (rAAV 2/2.hRPE65p.hRPE65))

Retinal Degeneration · Retinal Degeneration

#RetinalDegeneration#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleTargeted Genetics CorporationPhase 3

tgAAVCF (tgAAVCF)

Cystic Fibrosis · Cystic Fibrosis

#CysticFibrosis#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleEli LillyPhase 2

toripalimab + cetuximab + platinum (three cycles, three cycles (toripalimab + cetuximab + platinum))

Locally Advanced Hypopharyngeal Carcinoma · Locally Advanced Hypopharyngeal Carcinom

#LocallyAdvancedHypopharyngealCar#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Recruiting
AntibodyLimited DatastaleMatthew C. BakerPhase 3

LY3090106 (tibulizumab, tibulizumab (LY3090106))

Primary Sjogren's Syndrome · Primary Sjogren's Syndrome

#PrimarySjogrensSyndrome#Antibody#Phase3#monoclonal-antibody#Matthew
Trials 1Status Discontinued
AntibodyLimited DatastaleVanderbilt-Ingram Cancer CenterPreclinical

ticilimumab (ticilimumab)

Melanoma · Melanoma

#Melanoma#Antibody#Preclinical#monoclonal-antibody#Vanderbilt-Ingram
Trials 1Status Discontinued
AntibodyLimited DatastaleBeiGenePreclinical

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#monoclonal-antibody#NaturalKiller+3
Trials 1Status Active
AntibodyLimited DatastaleBeiGenePreclinical

tislelizumab, etoposide, pegaspargase (tislelizumab, etoposide, pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#monoclonal-antibody#NaturalKiller+3
Trials 1Status Active
AntibodyLimited DatastaleRocheApproved

tocilizumab [RoActemra/Actemra] (tocilizumab [RoActemra/Actemra])

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Discontinued
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

tositumomab (tositumomab)

Lymphoma, B-Cell · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#B-Cell+1
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 3

anti-CTLA4 (tremelimumab, tremelimumab (anti-CTLA4))

Non - Small Cell Lung Cancer NSCLC · Non - Small Cell Lung Cancer NSCLC

#Non-SmallCellLungCancerNSCLC#Antibody#Phase3#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

treme (tremelimumab, tremelimumab (treme))

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · Advanced Solid Tumors & Metastatic Squam

#AdvancedSolidTumorsMetastaticSqu#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, tremelimumab + durvalumab)

Advanced Malignancy · Advanced Malignancy

#AdvancedMalignancy#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

tremelimumab plus MEDI4736 (tremelimumab plus MEDI4736)

Pleural Mesothelioma; Peritoneal Mesothelioma · Pleural Mesothelioma

#PleuralMesothelioma#Antibody#Phase2#monoclonal-antibody#PeritonealMesothelioma+1
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

tremelimumab+MEDI4736 (tremelimumab+MEDI4736)

Metastatic Pancreatic Ductal Adenocarcinoma · Metastatic Pancreatic Ductal Adenocarcin

#MetastaticPancreaticDuctalAdenoc#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

uCD7 CART (uCD7 CART)

Acute Myeloid Leukemia (AML); T Lymphoblastic Leukemia/Lymphoma · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

umbilical cord blood CD19-BCMA CAR-T cells infusion (umbilical cord blood CD19-BCMA CAR-T cells infusion)

Refractory Lupus Nephritis; Systemic Sclerosis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMingfeng ZhaoPhase 1

universal CLL1 CAR-T cells (universal CLL1 CAR-T cells)

Acute Myeloid Leukemia; Chimeric Antigen Receptor T-cell · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBeth ChristianPhase 2

veltuzumab (veltuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Beth
Trials 1Status Active
AntibodyLimited DatastaleBeth ChristianPhase 2

veltuzumab and milatuzumab (veltuzumab and milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Beth
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, vinorelbine and trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting

120 / 121 pages

← PreviousNext →